Literature DB >> 31299535

Epilepsy in neurofibromatosis type 1: Diffuse cerebral dysfunction?

Esra Serdaroglu1, Bahadir Konuskan2, Kader Karli Oguz3, Gokce Gurler4, Dilek Yalnizoglu5, Banu Anlar6.   

Abstract

INTRODUCTION: Neurofibromatosis type 1 (NF1) is accompanied by epileptic seizures in 4-7% of patients. We examined clinical, electrophysiological, and radiological features associated with epilepsy in our NF1 series in order to identify risk factors.
METHODS: We reviewed data of 641 pediatric patients with NF1 diagnosis according to National Institutes of Health (NIH) criteria in Hacettepe University records from January 2008-August 2018. Demographic features, NF1-related clinical and imaging characteristics, age at onset of epilepsy, seizure semiology, and frequency, electroencephalogram (EEG) findings, and response to treatment were noted.
RESULTS: Twenty-six patients with NF1, 15 male, 11 female, had epilepsy. Age at seizure onset was 6 months to 13 years. Seizure semiology was focal with impaired awareness (n = 9, 34%), focal aware motor (n = 2, 8%), focal to bilateral tonic-clonic (n = 3, 12%), generalized tonic-clonic (n = 7, 28%), absence (n = 3, 12%), infantile spasms (n = 1), and unclassified type (n = 1). None had a history of status epilepticus. The EEG findings were normal for age in ten patients (38%). Others had focal (n = 8, 30%), generalized (n = 7, 27%), or multifocal (n = 1, 4%) discharges. On brain magnetic resonance imaging (MRI) signal intensity changes typical for NF1 (neurofibromatosis bright objects, NBOs) were the most common finding (80%), followed by normal MRI (20%). There was no relation between the localization of NBOs and discharges on EEG. Seventeen patients (65%) were seizure-free at the time of the study; 11 of them still under medication including four on multiple antiepileptic drugs. The rate of learning problems and NBO were significantly higher in patients with NF1 with epilepsy compared to those without. DISCUSSION: Epilepsy in NF1 is associated with relatively infrequent seizures and good response to treatment. Learning disorders are markedly frequent in this group, irrespective of the severity of epilepsy. The absence of correlation between the localizations of epileptiform discharges and lesions on MRI support the role of cellular or synaptic mechanisms rather than structural causes in the pathogenesis of epilepsy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; Learning difficulty; Neurofibromatosis bright objects; Neurofibromatosis type 1

Year:  2019        PMID: 31299535     DOI: 10.1016/j.yebeh.2019.06.022

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Epilepsy in NF1: a systematic review of the literature.

Authors:  Pia Bernardo; Giuseppe Cinalli; Claudia Santoro
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

Review 2.  Hippocampal sclerosis and epilepsy surgery in neurofibromatosis type 1: case report of a 3-year-old child explored by SEEG and review of the literature.

Authors:  Claudine Sculier; Delphine Taussig; Alec Aeby; Jerry Blustajn; Olivier Bekaert; Martine Fohlen
Journal:  Childs Nerv Syst       Date:  2021-09-10       Impact factor: 1.532

Review 3.  Electrophysiological and Behavioral Evidence for Hyper- and Hyposensitivity in Rare Genetic Syndromes Associated with Autism.

Authors:  Anastasia Neklyudova; Kirill Smirnov; Anna Rebreikina; Olga Martynova; Olga Sysoeva
Journal:  Genes (Basel)       Date:  2022-04-11       Impact factor: 4.141

4.  Epilepsy and Electroencephalogram Characteristics in Children with Neurofibromatosis Type 1, What We Have Learned from a Tertiary Center Five Years' Experience.

Authors:  Abdulhafeez M Khair; Stephen Falchek; Rahul Nikam; Gurcharanjeet Kaur
Journal:  Child Neurol Open       Date:  2022-10-11

5.  Epilepsy in NF1: Epidemiologic, Genetic, and Clinical Features. A Monocentric Retrospective Study in a Cohort of 784 Patients.

Authors:  Ugo Sorrentino; Silvia Bellonzi; Chiara Mozzato; Valeria Brasson; Irene Toldo; Raffaele Parrozzani; Maurizio Clementi; Matteo Cassina; Eva Trevisson
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.